FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject to	S
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

TATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	urden							
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Moretti August J (Last) (First) (Middle) C/O 4D MOLECULAR THERAPEUTICS INC. 5858 HORTON STREET #455							2. Issuer Name and Ticker or Trading Symbol 4D Molecular Therapeutics, Inc. [FDMT] 3. Date of Earliest Transaction (Month/Day/Year) 12/21/2022										ationship of Reporting Person(s) to Issuer ck all applicable) Director 10% Owner Officer (give title Other (specify below) Chief Financial Officer			
(Street)	VILLE C.	A	94608 (Zip)		4. If	Line) X Form file										filed by On	oint/Group Filing (Check Applicable led by One Reporting Person led by More than One Reporting			
		Tab	le I - Nor	n-Deriv	ative	e Se	curit	ies Ad	qui	ired, [Disp	osed o	of, or	Ben	eficial	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,			,	Transaction Dispos			rities Acquired (A) or ed Of (D) (Instr. 3, 4 a			Benefic	es ially Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									-	Code	v	Amount	(A) or (D) Pri		Price	Transac (Instr. 3	tion(s)			(1134: 4)
Common Stock 12/21					1/2022	/2022				M		3,00	3,000 A S		\$9.4	1 6,595(1)			D	
		ī	able II -									sed of onverti				Owned				
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transaction Code (Instr. 8)		of Deri Sec Acq (A) o Disp of (I	oosed D) tr. 3, 4	Exp	Date Exe piration I pnth/Day	Date	Amount of			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exe	e ercisable		xpiration ate	Title		Amount or Number of Shares					
Stock Option (Right to	\$9.41	12/21/2022			M			3,000		(2)	03	3/19/2029	Comm Stoc		3,000	\$0.00	220,00	50	D	

Explanation of Responses:

- 1. Reflects 1,595 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt from Rule 16b-3.
- 2. 25% of the shares subject to the option vest on the first anniversary measured from January 7, 2019 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

/s/ August J. Moretti

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.